Therapy insight: Fibromyalgia - A different type of pain needing a different type of treatment

Nature Clinical Practice Rheumatology

Volumn 2, Issue 7, 2006, Pages 364-372

  Dadabhoy, Dina ^a   Clauw, Daniel J ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Fatigue; Fibromyalgia; Pain; Pathophysiology; Treatment

Indexed keywords

4 AMINOBUTYRIC ACID DERIVATIVE; AMITRIPTYLINE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; BRAIN MONOAMINE; CATECHOL METHYLTRANSFERASE; CITALOPRAM; CLONAZEPAM; CYCLOBENZAPRINE; DOPAMINE 4 RECEPTOR; DULOXETINE; FLUOXETINE; GABAPENTIN; HYPNOTIC SEDATIVE AGENT; MILNACIPRAN; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; OPIATE DERIVATIVE; PAROXETINE; PRAMIPEXOLE; PREGABALIN; SEROTONIN 2A RECEPTOR; SEROTONIN 3 ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE; ZOPICLONE;

ANALGESIC ACTIVITY; AUTONOMIC NERVOUS SYSTEM; BEHAVIOR THERAPY; CENTRAL NERVOUS SYSTEM; CHRONIC PAIN; CLINICAL TRIAL; COGNITIVE THERAPY; DIABETIC NEUROPATHY; DOPAMINE BRAIN LEVEL; DOWN REGULATION; DRUG EFFICACY; DRUG RECEPTOR BINDING; ENVIRONMENTAL FACTOR; ENZYME INHIBITION; FIBROMYALGIA; GENETIC IDENTIFICATION; GENETIC RISK; HUMAN; KINESIOTHERAPY; MIGRAINE; NEUROENDOCRINE SYSTEM; NEUROPATHIC PAIN; NORADRENALIN BRAIN LEVEL; PAIN; PATIENT EDUCATION; POSTHERPETIC NEURALGIA; PREVALENCE; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; REVIEW; SEROTONIN BRAIN LEVEL; STRESS; SYMPTOMATOLOGY; TENSION HEADACHE; UNSPECIFIED SIDE EFFECT;

ANALGESICS; COGNITIVE THERAPY; EXERCISE THERAPY; FIBROMYALGIA; HUMANS; PAIN MEASUREMENT; TREATMENT OUTCOME;

EID: 33745753585     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0221     Document Type: Review

References (68)

1. Wolfe F et al. (1990) The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 33: 160-172
2. Wolfe F et al. (1995) Aspects of fibromyalgia in the general population: sex, pain threshold, and fibromyalgia symptoms. J Rheumatol 22: 151-156
3. Croft P et al. (1993) The prevalence of chronic widespread pain in the general population. J Rheumatol 20: 710-713
4. Wolfe F et al. (1995) The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 38: 19-28
5. Croft P et al. (1994) Population study of tender point counts and pain as evidence of fibromyalgia. Br Med J 309: 696-699
6. Petzke F et al. (2001) Dolorimetry performed at 3 paired tender points highly predicts overall tenderness. J Rheumatol 28: 2568-2569
7. Granges G and Littlejohn G (1993) Pressure pain threshold in pain-free subjects, in patients with chronic regional pain syndromes, and in patients with fibromyalgia syndrome. Arthritis Rheum 36: 642-646
8. Wolfe F (1997) The relation between tender points and fibromyalgia symptom variables: Evidence that fibromyalgia is not a discrete disorder in the clinic. Ann Rheum Dis 56: 268-271
9. Petzke F et al. (1999) Pain sensitivity in patients with fibromyalgia (FM): Expectancy effects on pain measurements. Arthritis Rheum 42: S342
10. Croft P et al. (1996) More pain, more tender points: Is fibromyalgia just one end of a continuous spectrum? Ann Rheum Dis 55: 482-485
11. Papageorgiou AC et al. (2002) Chronic widespread pain in the population: a seven year follow up study. Ann Rheum Dis 61: 1071-1074
12. Arnold LM et al. (2004) Family study of fibromyalgia. Arthritis Rheum 50: 944-952
13. Bondy B et al. (1999) The T102C polymorphism of the 5-HT2A-receptor gene in fibromyalgia. Neurobiol Dis 6: 433-439
14. Offenbaecher M et al. (1999) Possible association of fibromyalgia with a polymorphism in the serotonin transporter gene regulatory region. Arthritis Rheum 42: 2482-2488
15. Buskila D et al. (2004) An association between fibromyalgia and the dopamine D4 receptor exon III repeat polymorphism and relationship to novelty seeking personality traits. Mol Psychiatry 9: 730-731
16. Clauw DJ and Chrousos GP (1997) Chronic pain and fatigue syndromes: overlapping clinical and neuroendocrine features and potential pathogenic mechanisms. Neuroimmunomodulation 4: 134-153
17. Crofford LJ et al. (1994) Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum 37: 1583-1592
18. Demitrack MA and Crofford LJ (1998) Evidence for and pathophysiologic implications of hypothalamic-pituitary-adrenal axis dysregulation in fibromyalgia and chronic fatigue syndrome. Ann NY Acad Sci 840: 684-697
19. Qiao ZG et al. (1991) Electrodermal and microcirculatory activity in patients with fibromyalgia during baseline, acoustic stimulation and cold pressor tests. J Rheumatol 18: 1383-1389
20. Adler GK et al. (1999) Reduced hypothalamic-pituitary and sympathoadrenal responses to hypoglycemia in women with fibromyalgia syndrome. Am J Med 106: 534-543
21. Martinez-Lavin M et al. (1998) Circadian studies of autonomic nervous balance in patients with fibromyalgia: A heart rate variability analysis. Arthritis Rheum 41: 1966-1971
22. McBeth J et al. (2005) Hypothalamic-pituitary-adrenal stress axis function and the relationship with chronic widespread pain and its antecedents. Arthritis Res Ther 7: R992-R1000
23. Glass JM et al. (2004) The effect of brief exercise cessation on pain, fatigue, and mood symptom development in healthy, fit individuals. J Psychosom Res 57: 391-398
24. Lautenbacher S et al. (1994) Multi-method assessment of experimental and clinical pain in patients with fibromyalgia. Pain 59: 45-53
25. Gracely RH et al. (2002) Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum 46: 1333-1343
26. Price DD and Staud R (2005) Neurobiology of fibromyalgia syndrome. J Rheumatol Suppl 75: 22-28
27. Russell IJ et al. (1994) Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 37: 1593-1601
28. Sarchielli P et al. (2001) Levels of nerve growth factor in cerebrospinal fluid of chronic daily headache patients. Neurology 57: 132-134
29. Alpar EK et al. (2002) Management of chronic pain in whiplash injury. J Bone Joint Surg Br 84: 807-811
30. Suzuki R and Dickenson A (2005) Spinal and suparaspinal contributions to central sensitization in peripheral neuropathy. Neurosignals 14: 175-181
31. Kosek E et al. (1996) Sensory dysfunction in fibromyalgia patients with implications for pathogenic mechanisms. Pain 68: 375-383
32. Julien N et al. (2005) Widespread pain in fibromyalgia is related to a deficit of endogenous pain inhibition. Pain 114: 295-302
33. Baraniuk JN et al. (2004) Cerebrospinal fluid levels of opioid peptides in fibromyalgia and chronic low back pain. BMC Musculoskelet Disord 5: 48
34. Russell IJ et al. (1992) Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 35: 550-556
35. Yunus MB et al. (1992) Plasma tryptophan and other amino acids in primary fibromyalgia: A controlled study. J Rheumatol 19: 90-94
36. Hadler NM (1996) If you have to prove you are ill, you can't get well. The object lesson of fibromyalgia. Spine 21: 2397-2400
37. Hawley DJ and Wolfe F (1991) Pain, disability, and pain/disability relationships in seven rheumatic disorders: A study of 1,522 patients. J Rheumatol 18: 1552-1557
38. Callahan LF et al. (1989) Self-report questionnaires in five rheumatic diseases: Comparisons of health status constructs and associations with formal education level. Arthritis Care Res 2: 122-131
39. Turk DC et al. (1996) Pain, disability, and physical functioning in subgroups of patients with fibromyalgia. J Rheumatol 23: 1255-1262
40. Giesecke T et al. (2003) Subgrouping of fibromyalgia patients on the basis of pressure-pain thresholds and psychological factors. Arthritis Rheum 48: 2916-2922
41. Giesecke T et al. (2005) The relationship between depression, clinical pain, and experimental pain in a chronic pain cohort. Arthritis Rheum 52: 1577-1584
42. Gracely RH et al. (2004) Pain catastrophizing and neural responses to pain among persons with fibromyalgia. Brain 127: 835-843
43. Peters ML et al. (2000) Do fibromyalgia patients display hypervigilance for innocuous somatosensory stimuli? Application of a body scanning reaction time paradigm. Pain 86: 283-292
44. Goldenberg DL et al. (2004) Management of fibromyalgia syndrome. JAMA 292: 2388-2395
45. White KP et al. (2002) Does the label "fibromyalgia" alter health status, function, and health service utilization? A prospective, within-group comparison in a community cohort of adults with chronic widespread pain. Arthritis Rheum 47: 260-265
46. Arnold LM et al. (2000) Antidepressant treatment of fibromyalgia. A meta-analysis and review. Psychosomatics 41: 104-113
47. Capaci K and Hepguler S (2002) Comparison of the effects of amitriptyline and paroxetine in the treatment of fibromyalgia syndrome. Pain Clinic 14: 223-228
48. Anderberg UM et al. (2000) Citalopram in patients with fibromyalgia - a randomized, double-blind, placebo-controlled study. European Journal of Pain 4: 27-35
49. Norregaard J et al. (1995) A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain 61: 445-449
50. Fishbain D (2000) Evidence-based data on pain relief with antidepressants. Ann Med 32: 305-316
51. Adelman LC et al. (2000) Venlafaxine extended release (XR) for the prophylaxis of migraine and tension-type headache: A retrospective study in a clinical setting. Headache 40: 572-580
52. Gendreau RM et al. (2005) Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 32: 1975-1985
53. Arnold LM et al. (2004) A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 50: 2974-2984
54. Farber L et al. (2001) Short-term treatment of primary fibromyalgia with the 5-HT3-receptor antagonist tropisetron. Int J Clin Pharmacol Res 21: 1-13
55. Wiffen P et al. (2000) Anticonvulsant drugs for acute and chronic pain. The Cochrane Database Of Systematic Reviews, Issue 3, Art. No CD001133
56. Crofford LJ et al. (2005) Pregabalin for the treatment of fibromyalgia syndrome: Results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 52: 1264-1273
57. Redillas C and Solomon S (2000) Prophylactic pharmacological treatment of chronic daily headache. Headache 40: 83-102
58. Scharf MB et al. (2003) The effects of sodium oxybate on clinical symptoms and sleep patterns in patients with fibromyalgia. J Rheumatol 30: 1070-1074
59. Bennett RM (2001) Pharmacological treatment of fibromyalgia. J Funct Syndr 1: 79-92
60. Holman AJ and Myers RR (2005) A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum 52: 2495-2505
61. Russell IJ et al. (2002) Therapy with a central alpha 2-adrenergic agonist (tizanidine) decreases cerebrospinal fluid substance P, and may reduce serum hyaluronic acid as it improves the clinical symptoms of the fibromyalgia syndrome. Arthritis Rheum 46: S614
62. Williams DA et al. (2000) Randomized controlled trial of CBT to improve functional status in fibromyalgia. Am College Rheumatol 43: S210
63. Harris RE et al. (2005) Treatment of fibromyalgia with formula acupuncture: Investigation of needle placement, needle stimulation, and treatment frequency. J Altern Complement Med 11: 663-671
64. Assefi NP et al. (2005) A randomized clinical trial of acupuncture compared with sham acupuncture in fibromyalgia. Ann Intern Med 143: 10-19
65. Eisen S et al. (2005) Gulf War veterans' health: Medical evaluation of a U.S. cohort. Ann Intern Med 142: 881-890
66. Gray G et al. (2002) Self-reported symptoms and medical conditions among 11,868 Gulf War-era veterans: The Seabee Health Study. Am J Epidemiol 155: 1033-1044
67. Aaron LA et al. (2000) Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder. Arch Intern Med 160: 221-227
68. Aaron LA and Buchwald D (2001) A review of the evidence for overlap among unexplained clinical conditions. Ann Intern Med 134: 868-881